Dopaminergic D2 receptor knockout mouse: An animal model of prolactinoma

Frontiers of Hormone Research

Volumn 35, Issue , 2006, Pages 50-63

  Cristina, Carolina ^a   García Tornadú, Isabel ^a   Díaz Torga, Graciela ^a   Rubinstein, Marcelo ^b   Low, Malcolm J ^c   Becú Villalobos, Damasia ^a,d  

^a INST DE BIOL Y MED EXPERIMENTAL   (Argentina)

^b UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d Facultad de Ciencias Naturales e Instituto M Lillo   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE 2 RECEPTOR; VASCULAR ENDOTHELIAL GROWTH FACTOR A, MOUSE; VASCULOTROPIN A;

ANIMAL; CELL ADHESION; CONFERENCE PAPER; DISEASE MODEL; DRUG RESISTANCE; FEMALE; GENETICS; HYPERPLASIA; HYPOPHYSIS; HYPOPHYSIS TUMOR; MALE; MOUSE; MOUSE MUTANT; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PELIOSIS HEPATIS; PHYSIOLOGY; PROLACTINOMA; SEXUAL DEVELOPMENT; VASCULARIZATION;

ANIMALS; CELL ADHESION; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, NEOPLASM; FEMALE; HYPERPLASIA; MALE; MICE; MICE, KNOCKOUT; NEOVASCULARIZATION, PATHOLOGIC; PELIOSIS HEPATIS; PITUITARY GLAND; PITUITARY NEOPLASMS; PROLACTINOMA; RECEPTORS, DOPAMINE D2; SEX CHARACTERISTICS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 33745795815     PISSN: 03013073     EISSN: None     Source Type: Book Series    
DOI: 10.1159/000094308     Document Type: Conference Paper

References (39)

1. Ezzat S, Zheng L, Zhu XF, Wu GE, Asa SL: Targeted expression of a human pituitary tumor-derived isoform of FGF receptor-4 recapitulates pituitary tumorigenesis. J Clin Invest 2002;109:69-78.
2. McAndrew J, Paterson AJ, Asa SL, McCarthy KJ, Kudlow JE: Targeting of transforming growth factor-alpha expression to pituitary lactotrophs in transgenic mice results in selective lactotroph proliferation and adenomas. Endocrinology 1995;136:4479-4488.
3. Borrelli E, Sawchenko PE, Evans RM: Pituitary hyperplasia induced by ectopic expression of nerve growth factor. Proc Natl Acad Sci USA 1992:89:2764-2768.
4. Fedele M, Battista S, Kenyon L, Baldassarre G, Fidanza V, Klein-Szanto AJ, Parlow AF, Visone R, Pierantoni GM, Outwater E, Santoro M, Croce CM, Fusco A: Overexpression of the HMGA2 gene in transgenic mice leads to the onset of pituitary adenomas. Oncogene 2002:21:3190-3198.
5. Perumal P, Vrontakis ME: Transgenic mice over-expressing galanin exhibit pituitary adenomas and increased secretion of galanin, prolactin and growth hormone. J Endocrinol 2003:179:145-154.
6. Cai A, Hayes JD, Patel N, Hyde JF: Targeted overexpression of galanin in lactotrophs of transgenic mice induces hyperprolactinemia and pituitary hyperplasia. Endocrinology 1999:140:4955-4964.
7. Ikeda H, Yoshimoto T, Shida N, Miyoshi I, Nakayama K, Nakayama K, Oshima M, Taketo MM: Morphologic and molecular analysis of estrogen-induced pituitary tumorigenesis in targeted disruption of transforming growth factor-beta receptor type II and/or p27 mice. Endocrine 2001:16:55-65.
8. Schuff KG, Hentges ST, Kelly MA, Binart N, Kelly PA, Iuvone PM, Asa SL, Low MJ: Lack of prolactin receptor signaling in mice results in lactotroph proliferation and prolactinomas by dopamine-dependent and -independent mechanisms. J Clin Invest 2002:110:973-981.
9. Asa SL, Kelly MA, Grandy DK, Low MJ: Pituitary lactotroph adenomas develop after prolonged lactotroph hyperplasia in dopamine D2 receptor-deficient mice. Endocrinology 1999:140:5348-5355.
10. Kelly MA, Rubinstein M, Asa SL, Zhang G, Saez C, Bunzow JR, Allen RG, Hnasko R, Ben-Jonathan N, Grandy DK, Low MJ: Pituitary lactotroph hyperplasia and chronic hyperprolactinemia in dopamine D2 receptor-deficient mice. Neuron 1997:19:103-113.
11. Kelly MA, Rubinstein M, Phillips TJ, Lessovn CN, Burkhart-Kasch S, Zhang G, Bunzow JR, Fang Y, Gerhardt GA, Grandy DK, Low MJ: Locomotor activity in D2 dopamine receptor-deficient mice is determined by gene dosage, genetic background, and developmental adaptations. J Neurosci 1998:18:3470-3479.
12. Diaz-Torga G, Feierstein C, Libertun C, Gelman D, Kelly MA, Low MJ, Rubinstein M, Becu-Villalobos D: Disruption of the D2 dopamine receptor alters GH and IGF-I secretion and causes dwarfism in male mice. Endocrinology 2002:143:1270-1279.
13. Hentges ST, Low MJ: Ovarian dependence for pituitary tumorigenesis in D2 dopamine receptor-deficient mice. Endocrinology 2002:143:4536-4543.
14. Basu S, Nagy JA, Pal S, Vasile E, Eckelhoefer IA, Bliss VS, Manseau EJ, Dasgupta PS, Dvorak HF, Mukhopadhyay D: The neurotransmitter dopamine inhibits angiogenesis induced by vascular permeability factor/vascular endothelial growth factor. Nat Med 2001:7:569-574.
15. Chakroborty D, Sarkar C, Mitra RB, Banerjee S, Dasgupta PS, Basu S: Depleted dopamine in gastric cancer tissues: dopamine treatment retards growth of gastric cancer by inhibiting angiogenesis. Clin Cancer Res 2004:10:4349-4356.
16. Banerjee SK, Sarkar DK, Weston AP, De A, Campbell DR: Over expression of vascular endothelial growth factor and its receptor during the development of estrogen-induced rat pituitary tumors may mediate estrogen-initiated tumor angiogenesis. Carcinogenesis 1997:18:1155-1161.
17. Onofri C, Carbia NA, Schaaf L, Feirer M, Lohrer P, Stummer W, Berner S, Chervin A, Goldberg V, Stalla GK, Renner U, Arzt E: Estradiol stimulates vascular endothelial growth factor and interleukin-6 in human lactotroph and lactosomatotroph pituitary adenomas. Exp Clin Endocrinol Diabetes 2004:112:18-23.
18. Ferrara N, Gerber H, LeCouter J: The biology of VEGF and its receptors. Nat Med 2003:9: 669-676.
19. Ferrara N, Davis-Smyth T: The biology of vascular endothelial growth factor. Endocr Rev 1997:18:4-25.
20. Teunis MA, Kavelaars A, Voest E, Bakker JM, Ellenbroek BA, Cools AR, Heijnen CJ: Reduced tumor growth, experimental metastasis formation, and angiogenesis in rats with a hyperreactive dopaminergic system. FASEB J 2002:16:1465-1467.
21. Cristina C, Diaz-Torga G, Baldi A, Gongora A, Rubinstein M, Low MJ, Becu-Villalobos D: Increased pituitary vascular endothelial growth factor-A in dopaminergic D2 receptor knockout female mice. Endocrinology 2005:146:2952-2962.
22. Ochoa AL, Mitchner NA, Paynter CD, Morris RE, Ben Jonathan N: Vascular endothelial growth factor in the rat pituitary: differential distribution and regulation by estrogen. J Endocrinol 2000:165:483-492.
23. Vidal S, Kovacs K, Cohen SM, Stefaneanu L, Lloyd RV, Scheithauer BW: Localization of vascular endothelial growth factor in non tumorous human pituitaries. Endocr Pathol 1999:10:109-122.
24. Gospodarowicz D, Abraham JA, Schilling J: Isolation and characterization of a vascular endothelial mitogen produced by pituitary-derived folliculostellate cells. Proc Natl Acad Sci USA 1989:86:7311-7315.
25. Fan L, Iseki S: Immunohistochemical localization of vascular endothelial growth factor in the endocrine glands of the rat. Arch Histol Cytol 1998:61:17-28.
26. Stojilkovic SS: A novel view of the function of pituitary folliculo-stellate cell network. Trends Endocrinol Metab 2001:12:378-380.
27. Gloddek J, Pagotto U, Paez PM, Arzt E, Stalla GK, Renner U: Pituitary adenylate cyclase-activating polypeptide, interleukin-6 and glucocorticoids regulate the release of vascular endothelial growth factor in pituitary folliculostellate cells. J Endocrinol 1999:160:483-490.
28. Joseph F, Younis N, Haydon G, Adams DH, Wynne S, Gillet MB, Maurice YM, Lipton ME, Berstock D, Jones IR: Peliosis of the spleen with massive recurrent haemorrhagic ascites, despite splenectomy, and associated with elevated levels of vascular endothelial growth factor. Eur J Gastroenterol Hepatol 2004:16:1401-1406.
29. Park YN, Kim YB, Yang KM, Park C: Increased expression of vascular endothelial growth factor and angiogenesis in the early stage of multistep hepatocarcinogenesis. Arch Pathol Lab Med 2000:124:1061-1065.
30. Wong AK, Alfert M, Castrillon DH, Shen Q, Holash J, Yancopoulos GD, Chin L: Excessive tumor-elaborated VEGF and its neutralization define a lethal paraneoplastic syndrome. Proc Natl Acad Sci USA 2001:98:7481-7486.
31. Vidal S, Lloyd RV, Moya L, Scheithauer BW, Kovacs K: Expression and distribution of vascular endothelial growth factor receptor Flk-1 in the rat pituitary. J Histochem Cytochem 2002:50:533-540.
32. Yu R, Ren S-G, Horwitz GA, Wang Z, Melmed S: Pituitary tumor transforming gene (PTTG) regulates placental JEG-3 cell division and survival: evidence from live cell imaging. Mol Endocrinol 2000:14:1137-1146.
33. Kuchenbauer F, Theodoropoulou M, Hopfner U, Stalla J, Renner U, Tonn JC, Low MJ, Arzt E, Stalla GK, Paez-Pereda M: Laminin inhibits lactotroph proliferation and is reduced in early prolactinoma development. Mol Cell Endocrinol 2003:207:13-20.
34. Cristina C, Achaval-Zaia R, Baldi A, Low MJ, Rubinstein M, Diaz-Torga G, Becu-Villalobos D: Factores de crecimiento en la hiperplasia hipofisaria de ratones hembra deficientes en el receptor dopaminérgico tipo 2. Medicina 2000:62:469.
35. Ezzat S, Zheng L, Asa SL: Pituitary tumor-derived fibroblast growth factor receptor 4 isoform disrupts neural cell-adhesion molecule/N-cadherin signaling to diminish cell adhesiveness: a mechanism underlying pituitary neoplasia. Mol Endocrinol 2004:18:2543-2552.
36. Bergsland EK: Update on clinical trials targeting vascular endothelial growth factor in cancer. Am J Health Syst Pharm 2004:61:S12-S20.
37. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004:350:2335-2342.
38. Yamada S, Takada K: Angiogenesis in pituitary adenomas. Microsc Res Tech 2003:60:236-243.
39. Lloyd RV, Vidal S, Horvath E, Kovacs K, Scheithauer B: Angiogenesis in normal and neoplastic pituitary tissues. Microsc Res Tech 2003:60:244-250.